MedTrace Logo

Safety Study of Ointment for the Treatment of Plaque-type Psoriasis

NCT01258088 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-03-05

No results posted yet for this study

Summary

The purpose of this study is to determine how much drug is absorbed throughout the body after being applied to the skin.

Conditions

  • Plaque-type Psoriasis

Interventions

DRUG

AN2728 Ointment

5mg/cm2, BID

DRUG

AN2728 Vehicle

5mg/cm2 BID

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

  • Sepehr Shakib, MB BS, PhD · Royal Adelaide Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2010-12-07
Completion
2010-12-07

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01258088 on ClinicalTrials.gov